IVIG_related_ acute_kidney_injury

IVIG_related_ acute_kidney_injury - Tuesday Clinical Case...

Info iconThis preview shows pages 1–10. Sign up to view the full content.

View Full Document Right Arrow Icon
Tuesday Clinical Case Conference 11/2007 Zae Kim, MD
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Days after IVIG infusion u/o 600cc 800cc 3L 3L
Background image of page 2
IVIg-associated acute renal failure
Background image of page 3

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
IVIg-associated acute renal failure Overview IVIg? Epidemiology of IVIg related ARF Pathophysiology “osmotic nephrosis” vasoconstriction
Background image of page 4
Introduction - IVIG Collected from pooled human plasma, consisting mainly of immunoglobulin G subclass Initially developed in 1952 to treat primary immune deficiency syndrome First licensed by FDA in 1981 to treat six conditions: – primary immunodeficiencies – immune-mediated thrombocytopenia Kawasaki syndrome – recent bone marrow transplantation in patients aged greater than or equal to 20 years – chronic B-cell lymphocytic leukemia – pediatric human immunodeficiency virus type 1 (HIV-1) infection Used to treat 50-60 unapproved conditions
Background image of page 5

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
IVIG infusion related adverse reactions (fever, HA, myalgia, chills, nausea, and vomiting) thought to be 2/2 formation of immunoglobulin aggregates during manufacture or storage carbohydrates added to reduce aggregate formation Stabilized with Glucose, maltose, gycine, sucrose, sorbitol, or albumin In 1981, Gamimune became the first IGIV licensed in the United States. It was formulated with 10% maltose as a stabilizer to eliminate the severe adverse events
Background image of page 6
Acute Renal Failure After Large Doses of Intravenous Immune Globulin, Janet A Haskin, David J Warner, and Douglas U Blank, The Annals of Pharmacotherapy, 1999 July/August, Volume 33
Background image of page 7

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Product characteristics Safety and Adverse Events Profiles of Intravenous Gammaglobulin Products Used for Immunomodulation A Single-Center Experience_Ashley A. Vo_ Clin J Am Soc Nephrol 1 844-852, 2006 Gamunex Talecris 258 mOsm/kg 0 trace
Background image of page 8
Epidemiology – IVIg related ARF Incidence is unknown According to FDA report, approximately 120 reports worldwide (88 in the US) from 1985 -1998 Risk factors, based on available data from 54/88
Background image of page 9

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 10
This is the end of the preview. Sign up to access the rest of the document.

Page1 / 26

IVIG_related_ acute_kidney_injury - Tuesday Clinical Case...

This preview shows document pages 1 - 10. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online